Publikationen, an denen er mitarbeitet Sonia Eiras Penas (72)

2026

  1. Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 36, Núm. 4

  2. Corrigendum to ‘FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil’s proatherogenic phenotype which is modulated by semaglutide’(Journal of Molecular and Cellular Cardiology, (2026), 210, C, (12-27), (S0022282825001932), 10.1016/j.yjmcc.2025.10.009)

    Journal of Molecular and Cellular Cardiology

  3. External validation of atrial fibrillation risk scores in heart failure under continuous device surveillance

    Heart Rhythm

  4. FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide

    Journal of Molecular and Cellular Cardiology, Vol. 210, pp. 12-27

  5. Left ventricular ejection fraction determines the pattern of left atrial remodeling in patients with heart failure without atrial fibrillation

    Clinical Research in Cardiology

  6. Multiparametric assessment of atrial cardiopathy in cryptogenic stroke patients: Implications for personalized clinical management

    European stroke journal, Vol. 11, Núm. 1

2025

  1. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation, Vol. 55, Núm. 4

  2. Multiparametric assessment of atrial cardiopathy in cryptogenic stroke patients: Implications for personalized clinical management

    European Stroke Journal

  3. Plasma small extracellular vesicles: Markers and mediators of atrial scar, in patients with atrial fibrillation

    Heart Rhythm, Vol. 22, Núm. 12, pp. 3257-3267

  4. Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes

    JACC: Basic to Translational Science, Vol. 10, Núm. 9

2024

  1. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers

    Journal of Translational Medicine, Vol. 22, Núm. 1

  2. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry

    American Journal of Medicine, Vol. 137, Núm. 8, pp. 761-769.e1

  3. Endocrine activity of dysfunctional adipose tissue: Cardiovascular risk and progression markers

    International Journal of Cardiology

  4. Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial Fibrillation

    Journal of Cardiovascular Translational Research, Vol. 17, Núm. 1, pp. 13-23

  5. FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca2+ Dynamic Changes

    Circulation: Arrhythmia and Electrophysiology, Vol. 17, Núm. 9, pp. e012683

  6. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network

    Cardiovascular Diabetology, Vol. 23, Núm. 1

2023

  1. Clinical Profiling and Biomarkers for Post-Operative Atrial Fibrillation Prediction in Patients Undergoing Cardiac Surgery

    Journal of Clinical Medicine, Vol. 12, Núm. 10

  2. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  3. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators

    International journal of molecular sciences, Vol. 23, Núm. 14